Patient has positive ro60 antibodies at a titre of 460 , but negative ro60 igG antibodies. Please explain
Reading File
Finding Sources
Searching the Web
Ro60 antibody positive but negative Ro60 IgG explanation serology
Searching PubMed
anti-Ro60 antibody isotype IgG IgM IgA detection assay
Reading File
Reading Web Page
Ro60 antibody positive but IgG negative explanation isotype assay method
I now have enough information to give a thorough, well-sourced answer. Here is the explanation:
Positive Ro60 Antibodies with Negative Ro60 IgG - Explanation
This apparent discrepancy is almost entirely explained by assay methodology and immunoglobulin isotype differences, not by a biological paradox. Here is a structured breakdown:
1. The Two Tests Are Measuring Different Things
| Test | What it detects | Method used (typically) |
|---|---|---|
| Ro60 antibodies (total) | All immunoglobulin classes (IgG + IgM + IgA + IgE) directed at Ro60 antigen | Line immunoassay, immunodiffusion, ELISA with anti-total-Ig detection |
| Ro60 IgG antibodies | Only the IgG isotype directed at Ro60 antigen | Chemiluminescent immunoassay or ELISA with anti-IgG-specific secondary antibody (e.g., Mayo's method) |
When the total Ro60 assay is positive but the Ro60 IgG is negative, the anti-Ro60 antibodies present in the patient's serum are most likely of the IgM or IgA isotype, not IgG.
2. Why This Happens
Early/evolving autoimmune disease: In early connective tissue disease, the immune response may not yet have undergone full class-switching from IgM to IgG. IgM anti-Ro60 can appear first, before IgG emerges. The titre of 460 on the total assay is significant and not a borderline result, suggesting a genuine immune response - just not yet predominantly IgG.
IgA-predominant response: Some patients mount a predominantly mucosal/IgA response against Ro antigens, particularly in primary Sjogren syndrome where mucosal surfaces are involved. IgA anti-Ro antibodies are detected by total assays but missed by IgG-specific assays.
Assay sensitivity differences: The total Ro60 assay and the IgG-specific assay may use different antigen preparations, platforms (line blot vs. chemiluminescence vs. bead multiplex), and detection thresholds. A titre of 460 on one platform does not translate linearly to the other. Epitope masking, antigen conformation differences, and platform-specific calibration all contribute.
3. Key Technical Caveat from Mayo Clinic Laboratories
Mayo's own Ro60 IgG test notes explicitly:
"When assessed by standard SS-A (Ro) solid-phase immunoassays, some antibodies specific for Ro60 may not be detected due to masking of target epitopes. In addition, multiplex bead assays may simply be reported as SS-A/Ro positive without differentiation."
This means a positive on one platform and negative on another is a known occurrence, not an error.
4. Clinical Significance of the Discrepancy
Anti-Ro60 antibodies (regardless of isotype) are clinically important:
- Isolated anti-Ro60 (without anti-Ro52) is more strongly associated with SLE than with primary Sjogren syndrome
- Anti-Ro60 is associated with photosensitivity, leukopenia, hypocomplementemia, and secondary Sjogren overlap in SLE patients
- Anti-Ro60 IgG specifically carries the neonatal lupus / congenital heart block risk - this is the clinically important IgG-isotype concern. If the Ro60 IgG is truly negative (not just assay-discrepant), the risk of neonatal lupus in a pregnant patient is lower, though not zero if IgM/IgA is present.
- The ACR/EULAR 2016 classification criteria for Sjogren syndrome award 3 points for anti-SSA/Ro positivity - this includes any isotype detected by validated assays.
5. What to Do Clinically
- Do not discard the positive result. A titre of 460 on a total Ro60 assay is significant. Order full anti-ENA/ANA reflex panel if not already done.
- Consider repeat testing with a different platform (e.g., if first was line blot, repeat with chemiluminescence or ELISA, or vice versa).
- Check for anti-Ro52 separately - Ro52 and Ro60 are structurally distinct proteins with different clinical associations and must be reported independently.
- Context matters: Correlate with ANA titre/pattern, anti-dsDNA, complement levels, clinical features (sicca symptoms, rash, arthralgia).
- If patient is pregnant or planning pregnancy, the Ro60 IgG negative result is reassuring for congenital heart block risk - but clinical judgment and maternal-fetal medicine input are still required.
In summary: A positive Ro60 total antibody at a titre of 460 with a negative Ro60 IgG most likely reflects either an IgM or IgA isotype response, an assay platform/calibration discrepancy, or both. It is not contradictory - it simply means the immune response against Ro60 is real but not yet (or predominantly not) carried by IgG. The clinical significance of the Ro60 positivity is retained and should prompt further workup for connective tissue disease.
- Tietz Textbook of Laboratory Medicine, 7th Ed., p. 3786 - Anti-SSA-60 and anti-TRIM21 section
- Mayo Clinic Laboratories - Ro60 Antibody IgG test interpretation notes
The ana panel is negative for lupus antibodies, the only positive antibody is anti ro60. The patient presents with xerostomia and xerophtalmie, but he also has diabetes. The patient has pulmonary fibrosis, normal hemoleucogram. How to approach this case? What lab work should be investigated further?
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
Sjogren syndrome pulmonary fibrosis interstitial lung disease anti-Ro
Searching the Web
isolated anti-Ro60 positive Sjogren syndrome workup pulmonary fibrosis diabetes differential diagnosis
Reading File
Reading File
Searching PubMed
Sjogren syndrome interstitial lung disease diagnosis management
Reading File
Reading Web Page
Sjogren ILD diagnosis workup anti-Ro60 pulmonary fibrosis lab investigations
Finding Sources
Finding Sources
Reading File
A few key takeaways to anchor the clinical reasoning:
The diabetes warning is the most underappreciated issue here. Diabetic autonomic neuropathy causes genuine sicca symptoms indistinguishable from autoimmune sialadenitis on history alone. Because the patient already scores 3 points from anti-Ro60 alone - one point below the classification threshold - the lip biopsy is the deciding test. A positive biopsy (focus score ≥1) gives 3 additional points and firmly classifies pSjD regardless of diabetes. A negative biopsy raises serious doubt.
The missing anti-Ro52 is the single most important pending result. Isolated anti-Ro60 has a relatively weak association with ILD compared to anti-Ro52. If anti-Ro52 turns out to be positive (possibly missed on a panel that didn't separately report it), the entire picture shifts - the fibrosis becomes much more attributable to pSjD, the diagnosis solidifies, and the prognosis changes. Anti-Ro52 and anti-Ro60 must always be reported separately.
The HRCT pattern is the other anchor. UIP pattern on HRCT in a patient with borderline serology and diabetes may still represent IPF, and treating IPF with immunosuppression is harmful. NSIP, LIP, or OP patterns strongly favor CTD-ILD and support an autoimmune etiology. A multidisciplinary ILD team discussion (pulmonology + rheumatology + radiology) is the appropriate next step once imaging and serology are complete.
This is a shared conversation. Sign in to Orris to start your own chat.